RESEARKA

The human randomized controlled trial landscape for Curcumin inflammaging spans a remarkably broad range of clinical contexts, from type 2 diabetes and non-alcoholic fatty liver disease to rheumatoid arthritis, osteoarthritis, postmenopausal symptoms, and cognitive aging. Multiple systematic reviews and meta-analyses have been published in recent years, including umbrella reviews evaluating the totality of curcumin evidence across health outcomes (Xu 2025) and focused meta-analyses of lipid profiles (Unhapipatpong 2025), anthropometric indices in diabetes (Baniasadi 2025), rheumatoid arthritis disease activity (Fan 2026), and cognitive function (Wang 2025). Within the present corpus, positive effect directions have been reported for cardiometabolic endpoints including improvements in triglycerides, total cholesterol, and blood pressure in diabetic populations (Baniasadi 2025; Bahari 2025), and for functional endpoints such as reduced gastrointestinal symptoms in women with severe obesity (Kattah 2025). Immune and inflammatory endpoints show a particularly mixed profile, with some trials reporting significant reductions in pro-inflammatory cytokines (Yaikwawong 2026) and others finding no effect on inflammatory biomarkers (Lazou-Ahren 2024; Saleh 2025). The evidence base as a whole appears to support the conclusion that Curcumin inflammaging has a context-dependent profile, with the strongest signals in cardiometabolic and anti-inflammatory domains but persistent uncertainty regarding effect magnitude, durability, and clinical meaningfulness.

Citation Support

• source_1 Flensted-Jensen 2025
• source_2 Flensted-Jensen 2025b
• source_3 Xu 2025
• source_4 El-Rakabawy 2025
• source_5 Schonenberger 2025